logo
In world first, CCTV captures supershear velocity earthquake

In world first, CCTV captures supershear velocity earthquake

Yahoo6 days ago
Yahoo is using AI to generate takeaways from this article. This means the info may not always match what's in the article. Reporting mistakes helps us improve the experience.
Yahoo is using AI to generate takeaways from this article. This means the info may not always match what's in the article. Reporting mistakes helps us improve the experience.
Yahoo is using AI to generate takeaways from this article. This means the info may not always match what's in the article. Reporting mistakes helps us improve the experience. Generate Key Takeaways
Earthquakes are violent events that alter the face of the planet. In many cases, those changes occur beneath the surface and only gradually become visible over thousands of years. Occasionally, however, an earthquake's effects aren't just felt—they're seen. It's even rarer to actually capture one of those moments on camera, but according to seismologists at Japan's Kyoto University, the footage highlights the first-known video of a strike-slip fault. Their analysis, published in The Seismic Record, has led to new findings based on real-time visual evidence of tectonic motion.
The magnitude 7.7 event took place on March 28 along the Sagaing Fault with an epicenter near Myanmar's second-largest city, Mandalay. Although the initial rupture process lasted barely 80 seconds, it and numerous aftershocks were ultimately responsible for 5,456 confirmed deaths and over 11,000 injuries. Later evaluations indicated the quake was the second deadliest in modern history, as well as the most powerful to hit Myanmar in over a century. According to a separate group's paper published in the same journal, the southern portion of the rupture occurred at an astonishing 3.7 miles per second—fast enough to qualify as 'supershear velocity.'
Amid the catastrophe, an outdoor CCTV camera about 74.5 miles south of the epicenter recorded a visceral illustration of its power. Over just a few moments, what at first looks like a single chunk of the ground appears to suddenly divide and horizontally shift past one another in opposite directions. Completely by accident, the camera recorded a direct look of a strike-slip fault, something previously analyzed by remote seismic instruments. To researchers at Kyoto University, the clip wasn't just a jaw-dropping scene—it was an opportunity to study a strike-slip fault using visual data.
Geologists analyzed the brief video frame-by-frame to learn about the fault shift. Credit: KyotoU / Jesse Kearse
'We did not anticipate that this video record would provide such a rich variety of detailed observations,' corresponding author and geologist Jesse Kearse said in a statement. 'Such kinematic data is critical for advancing our understanding of earthquake source physics.'
Kearse and colleagues utilized a technique called pixel cross-correlation to analyze the fault movement on a frame-by-frame basis. Their findings showed the fault slipped horizontally by 8.2 feet in only 1.3 seconds, with a maximum speed of about 10.5 feet per second. While the movement matched experts' existing knowledge of strike-slip ruptures, the short duration and speed were new developments.
'The brief duration of motion confirms a pulse-like rupture, characterized by a concentrated burst of slip propagating along the fault, much like a ripple traveling down a rug when flicked from one end,' Kearse explained.
Additional examinations also proved that the slip path was slightly curved, confirming previous observations recorded elsewhere in the world. This means subtly curving strike-slips instead of totally linear ones may be the rule, not the exception.
'Overall, these observations establish a new benchmark for understanding dynamic rupture processes,' the study's authors wrote, adding that the video offers real-time confirmation of curved slip paths while helping 'deepen our understanding of the physical mechanisms that control rapid fault slip during large earthquakes.'
Such discoveries may also help seismologists, geologists, and urban planners design more resilient architecture to ensure that when major earthquakes inevitably occur, their damage is minimized as much as possible.
Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

How China's military went from obsolete to world-class
How China's military went from obsolete to world-class

Yahoo

time4 hours ago

  • Yahoo

How China's military went from obsolete to world-class

Dive into the strengths and weaknesses of China's military and its remarkable transformation over the last few decades from obsolete to world-class in a new special series on Battle Lines. How significant is China's military buildup? What does Xi Jinping's ongoing purge mean for the People's Liberation Army? And how likely is an invasion of Taiwan in the next few years? As the US pivots to the Indo-Pacific and the threat of a truly global war looms, understanding the evolving role of China's military on the world stage has never been more important. In episode one of this three-part series, Venetia Rainey uncovers the strengths that define the PLA today, from its vastly modernised Navy, now the largest globally, to its Air Force equipped with stealth fighters and advanced drones. Plus, a look at China's potent non-conventional forces, such as its highly sophisticated cyber warfare units, its independent aerospace and counter-space capabilities, and the secretive Rocket Force, responsible for a fast-expanding nuclear arsenal. Broaden your horizons with award-winning British journalism. Try The Telegraph free for 1 month with unlimited access to our award-winning website, exclusive app, money-saving offers and more. Solve the daily Crossword

Hengrui Pharma and GSK link across key therapeutic areas
Hengrui Pharma and GSK link across key therapeutic areas

Yahoo

time5 hours ago

  • Yahoo

Hengrui Pharma and GSK link across key therapeutic areas

Hengrui Pharma has signed an agreement with GSK for the development of up to 12 innovative medicines across several therapeutic areas, including respiratory, immunology and inflammation, and oncology. The collaboration is poised to enhance Hengrui's globalisation strategy and provide GSK with significant growth opportunities beyond 2031. GSK will pay an upfront fee of $500m, which includes licensing for the phosphodiesterase (PDE)3/4 programme. The potential value of future success-based payments to Hengrui Pharma could be close to $12bn, assuming all programmes are optioned and milestones met. Hengrui Pharma is also set to receive tiered royalties on worldwide product net sales, with certain regional exclusions. A highlight of the agreement is the worldwide licence for HRS-9821, a PDE3/4 inhibitor in clinical development for chronic obstructive pulmonary disease (COPD). HRS-9821 aligns with GSK's goal to address a broad spectrum of COPD patients, including those with ongoing dyspnoea or those less likely to be prescribed inhaled corticosteroids or biologics. In early trials, this inhibitor showed positive anti-inflammatory and bronchodilation effects. Its potential for a dry-powder inhaler formulation could integrate well with GSK's existing inhaled portfolio. Hengrui Pharma executive vice-president and chief strategy officer Frank Jiang stated: 'GSK brings additional research and development expertise, a robust global clinical network and broad regulatory capabilities that will accelerate our PDE3/4 inhibitor as well as an array of other innovative therapy programmes to overseas markets, potentially delivering breakthrough treatments to patients globally." Beyond HRS-9821, the collaboration includes up to 11 additional programmes. Hengrui Pharma will spearhead the development up to Phase I trials, after which GSK may opt to develop further and commercialise the programmes globally, excluding mainland China, the Macau special administrative region (SAR), Hong Kong SAR and Taiwan. This scaled collaboration is designed to expedite the development of innovative medicines, leveraging GSK's expertise and global reach alongside Hengrui Pharma's discovery and clinical evaluation capabilities. The licensing of HRS-9821 is contingent upon customary regulatory clearances, including under the Hart-Scott-Rodino Act in the US. In March 2025, MSD entered an exclusive licence agreement with Hengrui Pharma for the investigational oral small-molecule lipoprotein(a) [Lp(a)] inhibitor, HRS-5346. "Hengrui Pharma and GSK link across key therapeutic areas" was originally created and published by Pharmaceutical Technology, a GlobalData owned brand.

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into a world of global content with local flavor? Download Daily8 app today from your preferred app store and start exploring.
app-storeplay-store